Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Sleep Apnea Syndromes

ClinicalTrials.gov lists 2,929 trials for Sleep Apnea Syndromes or a narrower condition beneath it. ResMed has the most among industry and government lead sponsors, with 69.

MeSH D012891 Respiratory Tract Diseases C08 C10
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 60 Phase 1/2 Phase 1/2 38 Phase 2 Phase 2 108 Phase 2/3 Phase 2/3 27 Phase 3 Phase 3 102 Phase 4 Phase 4 147 Not applicable Not applicable 1,496 Observational Observational 947 Phase 1 Phase 1 60 Phase 1/2 Phase 1/2 38 Phase 2 Phase 2 108 Phase 2/3 Phase 2/3 27 Phase 3 Phase 3 102 Phase 4 Phase 4 147 Not applicable Not applicable 1,496 Observational Observational 947

Trials per phase (log scale)

2 more sections with rows

1,074 of the 2,929 trials are tagged with Sleep Apnea Syndromes itself; the rest are tagged with a narrower condition beneath it.

Get the Sleep Apnea Syndromes report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Sleep Apnea Syndromes trials start? (33)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 6 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 184

1990: 3 trials (Observational 3) 1993: 1 trials (Observational 1) 1994: 2 trials (Observational 2) 1995: 2 trials (Observational 2) 1998: 4 trials (Observational 3, Phase 2 1) 1999: 8 trials (Observational 6, Phase 4 1, Phase 2/3 1) 2000: 4 trials (Not applicable 1, Phase 4 2, Phase 2/3 1) 2001: 10 trials (Observational 4, Not applicable 3, Phase 4 1, Phase 3 1, Phase 1 1) 2002: 5 trials (Observational 2, Not applicable 1, Phase 3 1, Phase 2 1) 2003: 21 trials (Observational 6, Not applicable 8, Phase 4 2, Phase 3 1, Phase 2 3, Phase 1 1) 2004: 40 trials (Observational 5, Not applicable 13, Phase 4 8, Phase 3 8, Phase 2 5, Phase 1 1) 2005: 44 trials (Observational 9, Not applicable 24, Phase 4 5, Phase 3 3, Phase 2 2, Phase 1 1) 2006: 45 trials (Observational 13, Not applicable 20, Phase 4 4, Phase 3 2, Phase 2/3 1, Phase 2 2, Phase 1/2 1, Phase 1 2) 2007: 77 trials (Observational 26, Not applicable 31, Phase 4 8, Phase 3 8, Phase 2 3, Phase 1 1) 2008: 94 trials (Observational 28, Not applicable 39, Phase 4 10, Phase 3 7, Phase 2/3 2, Phase 2 5, Phase 1/2 1, Phase 1 2) 2009: 97 trials (Observational 30, Not applicable 50, Phase 4 4, Phase 3 3, Phase 2/3 3, Phase 2 2, Phase 1/2 2, Phase 1 3) 2010: 114 trials (Observational 36, Not applicable 52, Phase 4 4, Phase 3 6, Phase 2/3 2, Phase 2 8, Phase 1/2 4, Phase 1 2) 2011: 108 trials (Observational 26, Not applicable 54, Phase 4 4, Phase 3 10, Phase 2/3 2, Phase 2 5, Phase 1/2 2, Phase 1 5) 2012: 102 trials (Observational 30, Not applicable 52, Phase 4 7, Phase 3 7, Phase 2/3 1, Phase 2 3, Phase 1/2 1, Phase 1 1) 2013: 111 trials (Observational 27, Not applicable 68, Phase 4 8, Phase 2/3 1, Phase 2 2, Phase 1/2 2, Phase 1 3) 2014: 152 trials (Observational 48, Not applicable 83, Phase 4 10, Phase 3 4, Phase 2/3 3, Phase 2 2, Phase 1/2 1, Phase 1 1) 2015: 147 trials (Observational 36, Not applicable 90, Phase 4 6, Phase 3 4, Phase 2/3 1, Phase 2 6, Phase 1 4) 2016: 164 trials (Observational 47, Not applicable 98, Phase 4 10, Phase 3 2, Phase 2/3 1, Phase 2 3, Phase 1/2 1, Phase 1 2) 2017: 165 trials (Other 1, Observational 59, Not applicable 95, Phase 4 2, Phase 3 1, Phase 2 4, Phase 1/2 2, Phase 1 1) 2018: 147 trials (Other 1, Observational 55, Not applicable 73, Phase 4 9, Phase 2/3 1, Phase 2 3, Phase 1/2 2, Phase 1 3) 2019: 184 trials (Observational 63, Not applicable 95, Phase 4 9, Phase 3 4, Phase 2 3, Phase 1/2 3, Phase 1 7) 2020: 141 trials (Observational 44, Not applicable 78, Phase 4 2, Phase 2/3 1, Phase 2 12, Phase 1/2 1, Phase 1 3) 2021: 152 trials (Observational 58, Not applicable 76, Phase 4 6, Phase 2 5, Phase 1/2 2, Phase 1 5) 2022: 151 trials (Observational 47, Not applicable 83, Phase 4 5, Phase 3 3, Phase 2/3 2, Phase 2 5, Phase 1/2 2, Phase 1 4) 2023: 141 trials (Observational 55, Not applicable 58, Phase 4 5, Phase 3 6, Phase 2/3 1, Phase 2 9, Phase 1/2 5, Phase 1 2) 2024: 160 trials (Observational 60, Not applicable 79, Phase 4 9, Phase 3 1, Phase 2/3 1, Phase 2 6, Phase 1/2 1, Phase 1 3) 2025: 163 trials (Other 1, Observational 64, Not applicable 85, Phase 4 1, Phase 3 5, Phase 2 4, Phase 1/2 2, Phase 1 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 139
2025 163
2024 160
2023 141
2022 151
2021 152
2020 141
2019 184
2018 147
2017 165

Forecast of the full-year count, planned starts included, not rows of this table: about 160 trials starting in 2026 and about 160 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 207 trials still running at the 2026-10-09 snapshot; registered median of 23 months across 1,809 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Sleep Apnea Syndromes trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 60
Phase 1/2 38
Phase 2 108
Phase 2/3 27
Phase 3 102
Phase 4 147
Not applicable 1,496
Observational 947
Expanded access 1
Unknown 3

How many Sleep Apnea Syndromes trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 124
Recruiting 311
Enrolling by invitation 35
Active, not recruiting 65
Available 1

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Sleep Apnea Syndromes trials? (3)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
ResMed 69
Fisher and Paykel Healthcare 68
VA Office of Research and Development 43

Which drugs are being tested for Sleep Apnea Syndromes? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
DEXMEDETOMIDINE 11
Trazodone 9
Solriamfetol 8
PROPOFOL 8
Armodafinil 7

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Acetazolamide Pill 24
Eszopiclone 3 mg QHS 11
Drug-Induced Sleep Endoscopy (Propofol) 10
Control (placebo) group 9
Medicinal gas - oxygen (Nippon Gases 200 bar) 9

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Sleep Apnea Syndromes trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Second secondary endpoint 947 1
Hospitalization for any cause 900 1
Primary end point 695 1
Firt secondary endpoint 662 1
Unplanned hospitalization for worsening heart failure 559 1

Which publications cover Sleep Apnea Syndromes? (1,173)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Sub-conditions in MeSH (2)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages